Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT05117125 · Pneumonia, Ventilator-Associated
NCT06834971 · Ventilator-Associated Pneumonia (VAP)
NCT06966310 · Community-acquired Pneumonia
NCT00001352 · Cryptococcal Infection, Cryptococcal Pneumonia, and more
NCT07552779 · Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), and more
Mobile, Alabama
Loma Linda, California
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions